In a small US trial, a diet that mimics fasting for five days a month helped more adults with mild-to-moderate Crohn's disease feel better than staying on their usual diet. People on the diet also had a modest fall in a marker of gut inflammation. The results are encouraging but early, and the way the trial was run makes them harder to interpret.
The study, led by Stanford Medicine in California, was published in the journal Nature Medicine in January 2026 and has recently been reported again in the news.
What the trial tested
A fasting-mimicking diet is a very low-calorie meal plan designed to copy some of the effects of fasting while still letting people eat. In this trial it came as a ready-made box of soups, bars, snacks and supplements sold by a US company, L-Nutra. It provided about 1,090 calories on day one and 725 calories a day on days two to five. The food is plant-based, low in protein and sugar, and high in unsaturated fats.
The researchers recruited 97 adults aged 18 to 70 with mild-to-moderate Crohn's through 59 institutions across the US. They were randomised, meaning chosen by chance, with 65 put on the diet and 32 staying on their normal diet. The diet group followed the plan for five days each month for three months and ate normally the rest of the time. Everyone kept taking their usual Crohn's medicines.
What the study found
Symptoms were measured with the Crohn's Disease Activity Index (CDAI), a symptom score that is partly based on what patients report themselves. A lower score means milder disease.
After three months, 69.2% of people on the diet (45 of 65) had a clinical response, meaning their score fell by at least 70 points or ended at 150 or below. This compared with 43.8% (14 of 32) of those on their usual diet. Remission, defined here as a score of 150 or below, was reached by 64.6% of the diet group and 37.5% of the comparison group.
Faecal calprotectin, a protein in stools that rises when the gut is inflamed, fell by 22.0% in the diet group and rose by 8.0% in the comparison group. The researchers also saw falls in some inflammatory fat molecules and in immune gene activity, but these were exploratory findings that need confirming.
Side effects and sticking with the diet
No severe side effects were reported in the diet group. About half had tiredness (52.3%) or headaches (50.8%), mostly mild, and weight did not change significantly. In the comparison group, seven people (21.8%) reported severe side effects.
Just over three-quarters (76.9%) of the diet group completed all three five-day cycles. Fourteen people (21.5%) dropped out of the diet group and three (9.4%) from the comparison group. The authors say none of these withdrawals were caused by side effects.
Why caution is needed
The trial was open-label, so everyone knew which diet they were on. Because the main result is a symptom score that patients partly report themselves, expectations could have affected it. Both the authors and an independent commentary describe this as the study's biggest limitation.
About two-thirds of participants had mild disease, so the results say little about more severe Crohn's. Too few people had a colonoscopy (a camera test of the bowel) to show whether the gut lining actually healed.
The two groups were also different at the start. The diet group included more women (80% compared with 56%) and more people with stricturing disease, where the bowel has become narrowed. The comparison group had more people with obesity and more people taking anti-TNF medicines, a type of biologic treatment. The study was small and lasted only three months.
One of the authors, Valter Longo, owns shares in L-Nutra and has filed patents on the diet. He says he takes no consulting fees and has committed his shares to charity. The research was funded by the Helmsley Charitable Trust, the US National Institutes of Health and others.
What it means for you
The trial's senior author, Dr Sidhartha Sinha, says the diet is meant to be used alongside standard medical treatment, not instead of it. Everyone in the study stayed on their medicines.
Because it is a diet rather than a medicine, it does not need a licence from the Medicines and Healthcare products Regulatory Agency (MHRA). We have not been able to confirm whether NICE, which advises the NHS, has looked at fasting-mimicking diets, or whether they are available on the NHS. We also don't know whether the meal kit used in the trial is sold in the UK.
The trial only included adults with milder disease, all in the US. It tells us nothing about children and teenagers, people with severe Crohn's, or anyone thinking of using the diet in place of treatment.
What happens next
Larger and longer trials would be needed to show whether the benefits are real and lasting. Ideally these would include colonoscopy results and other measures that do not depend on how people feel.
If you are interested in trying a very low-calorie diet like this, talk to your IBD team or a dietitian first, and keep taking your medicines unless they advise otherwise. You can read more about diets already used to treat Crohn's in our guide to elemental and polymeric diets, and about weighing up the options in Should I go for drugs or diet?
Ref: Kulkarni C, Fardeen T et al. Nature Medicine 2026;32:1023–33. https://www.nature.com/articles/s41591-025-04173-w